$EXEL
EXELIXIS, INC.

2022 Q1 Form 10-K Financial Statement

#000093976722000026 Filed on February 18, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $356.0M $328.4M $270.1M
YoY Change 31.82% 42.12% 19.02%
Cost Of Revenue $13.20M $11.87M $13.20M
YoY Change 0.02% 36.09% 41.94%
Gross Profit $342.8M $316.5M $191.3M
YoY Change 79.17% 98.01% -12.08%
Gross Profit Margin 96.29% 96.38% 70.84%
Selling, General & Admin $102.9M $101.6M $102.4M
YoY Change 0.45% 15.16% 62.8%
% of Gross Profit 30.01% 32.08% 53.52%
Research & Development $156.7M $163.4M $159.3M
YoY Change -1.65% -7.58% 56.33%
% of Gross Profit 45.71% 51.61% 83.27%
Depreciation & Amortization $4.490M $1.931M $3.200M
YoY Change 40.31% -19.54% 45.45%
% of Gross Profit 1.31% 0.61% 1.67%
Operating Expenses $259.5M $264.9M $261.6M
YoY Change -0.79% -0.01% 58.74%
Operating Profit $83.24M $51.62M $24.30M
YoY Change 242.61% -221.23% -53.98%
Interest Expense $1.822M $1.441M $2.700M
YoY Change -32.52% -58.83% -62.5%
% of Operating Profit 2.19% 2.79% 11.11%
Other Income/Expense, Net $164.0K -$19.00K -$100.0K
YoY Change -264.0% -103.36%
Pretax Income $85.23M $118.0M -$2.000M
YoY Change -4361.45% -410.41% -103.33%
Income Tax $16.66M $15.06M -$3.600M
% Of Pretax Income 19.54% 12.76%
Net Earnings $68.57M $38.20M $28.39M
YoY Change 141.56% -219.24% -41.59%
Net Earnings / Revenue 19.26% 11.63% 10.51%
Basic Earnings Per Share $0.12 $0.09
Diluted Earnings Per Share $212.1K $0.12 $0.09
COMMON SHARES
Basic Shares Outstanding 319.4M shares 315.4M shares 312.0M shares
Diluted Shares Outstanding 322.0M shares

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.570B $1.467B $1.186B
YoY Change 32.46% 21.6% 24.21%
Cash & Equivalents $723.3M $647.2M $319.2M
Short-Term Investments $847.1M $819.9M $815.3M
Other Short-Term Assets $53.33M $57.53M $46.30M
YoY Change 15.19% 0.93% 55.37%
Inventory $28.47M $27.49M $20.97M
Prepaid Expenses
Receivables $190.6M $282.7M $177.7M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.843B $1.835B $1.445B
YoY Change 27.49% 30.33% 42.94%
LONG-TERM ASSETS
Property, Plant & Equipment $106.2M $104.0M $67.38M
YoY Change 57.56% 84.5% 37.82%
Goodwill $63.68M $63.68M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $404.5M $371.1M $279.1M
YoY Change 44.94% 11.68% -42.38%
Other Assets $233.8M $131.0M $73.41M
YoY Change 218.43% 88.74% 38.13%
Total Long-Term Assets $811.4M $781.5M $691.9M
YoY Change 17.26% 11.13% -20.87%
TOTAL ASSETS
Total Short-Term Assets $1.843B $1.835B $1.445B
Total Long-Term Assets $811.4M $781.5M $691.9M
Total Assets $2.654B $2.616B $2.137B
YoY Change 24.18% 23.93% 13.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.29M $24.26M $23.63M
YoY Change -26.86% -49.39% 104.06%
Accrued Expenses $158.1M $226.3M $111.2M
YoY Change 42.22% 95.23% 58.18%
Deferred Revenue $7.814M $1.790M
YoY Change 501.08%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $289.1M $337.6M $204.7M
YoY Change 41.25% 67.67% 43.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $71.19M $8.023M $721.0K
YoY Change 9773.51% 1012.76% -69.28%
Total Long-Term Liabilities $71.19M $8.023M $721.0K
YoY Change 9773.51% 1012.76% -69.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $289.1M $337.6M $204.7M
Total Long-Term Liabilities $71.19M $8.023M $721.0K
Total Liabilities $360.3M $405.6M $258.2M
YoY Change 39.52% 56.6% 29.3%
SHAREHOLDERS EQUITY
Retained Earnings -$216.5M -$447.6M
YoY Change -54.51% -19.98%
Common Stock $319.0K $312.0K
YoY Change 3.24% 2.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.294B $2.211B $1.879B
YoY Change
Total Liabilities & Shareholders Equity $2.654B $2.616B $2.137B
YoY Change 24.18% 23.93% 13.35%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income $68.57M $38.20M $28.39M
YoY Change 141.56% -219.24% -41.59%
Depreciation, Depletion And Amortization $4.490M $1.931M $3.200M
YoY Change 40.31% -19.54% 45.45%
Cash From Operating Activities $147.7M $96.45M $39.50M
YoY Change 273.97% 189.65% -29.59%
INVESTING ACTIVITIES
Capital Expenditures -$5.609M -$15.96M -$13.60M
YoY Change -58.76% 12.39% 353.33%
Acquisitions
YoY Change
Other Investing Activities -$68.93M $2.905M $75.80M
YoY Change -190.94% -119.11% 112.92%
Cash From Investing Activities -$74.54M -$13.06M $62.30M
YoY Change -219.65% -55.75% 91.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 205.0K -17.99M -2.700M
YoY Change -107.59% -3.78% -228.57%
NET CHANGE
Cash From Operating Activities 147.7M 96.45M 39.50M
Cash From Investing Activities -74.54M -13.06M 62.30M
Cash From Financing Activities 205.0K -17.99M -2.700M
Net Change In Cash 73.39M 65.40M 99.10M
YoY Change -25.95% -538.95% 9.14%
FREE CASH FLOW
Cash From Operating Activities $147.7M $96.45M $39.50M
Capital Expenditures -$5.609M -$15.96M -$13.60M
Free Cash Flow $153.3M $112.4M $53.10M
YoY Change 188.75% 136.66% -10.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000939767
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Security12b Title
Security12bTitle
Common Stock $.001 Par Value per Share
CY2021 dei Trading Symbol
TradingSymbol
EXEL
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
000-30235
CY2021 dei Entity Registrant Name
EntityRegistrantName
EXELIXIS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3257395
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1851 Harbor Bay Parkway
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Alameda,
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94502
CY2021 dei City Area Code
CityAreaCode
650
CY2021 dei Local Phone Number
LocalPhoneNumber
837-7000
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Public Float
EntityPublicFloat
5680065864 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
319448174 shares
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Redwood City, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
647169000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
319217000 USD
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
819905000 USD
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
887319000 USD
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
282650000 USD
CY2021Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
160875000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
27493000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
20973000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
57530000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
57011000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1834747000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
1445395000 USD
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
371112000 USD
CY2021Q1 us-gaap Long Term Investments
LongTermInvestments
330751000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
104031000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67384000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
111663000 USD
CY2021Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
156711000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
63684000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
63684000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131002000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73408000 USD
CY2021Q4 us-gaap Assets
Assets
2616239000 USD
CY2021Q1 us-gaap Assets
Assets
2137333000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
24258000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
23632000 USD
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
61969000 USD
CY2021Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
51189000 USD
CY2021Q4 exel Accrued Clinical Liabilities Current
AccruedClinicalLiabilitiesCurrent
77544000 USD
CY2021Q1 exel Accrued Clinical Liabilities Current
AccruedClinicalLiabilitiesCurrent
52251000 USD
CY2021Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
33700000 USD
CY2021Q1 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
20683000 USD
CY2021Q4 exel Accrued Collaboration Liability Current
AccruedCollaborationLiabilityCurrent
86753000 USD
CY2021Q1 exel Accrued Collaboration Liability Current
AccruedCollaborationLiabilityCurrent
12456000 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
53366000 USD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44447000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
337590000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
204658000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8739000 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3755000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51272000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49086000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8023000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
721000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
405624000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
258220000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
318842000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
318842000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
311627000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
311627000 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
319000 USD
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
312000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2427561000 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2321895000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-758000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4476000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216507000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-447570000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2210615000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1879113000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2616239000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2137333000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1434970000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
987538000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
967775000 USD
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
52873000 USD
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36272000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33097000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
693716000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
547851000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
336964000 USD
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
401715000 USD
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
293355000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
228244000 USD
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
1148304000 USD
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
877478000 USD
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
598305000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
286666000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
110060000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
369470000 USD
CY2021 us-gaap Interest Income Other
InterestIncomeOther
7672000 USD
CY2021 us-gaap Interest Income Other
InterestIncomeOther
19865000 USD
CY2020 us-gaap Interest Income Other
InterestIncomeOther
27959000 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-184000 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
912000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
680000 USD
CY2021 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
294154000 USD
CY2021 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
130837000 USD
CY2020 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
398109000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63091000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19056000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77097000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
111781000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
321012000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.73
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
314884000 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
308271000 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
302584000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
322359000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
318001000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
315009000 shares
CY2021 us-gaap Net Income Loss
NetIncomeLoss
111781000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
321012000 USD
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1481000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-394000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-1049000 USD
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5234000 USD
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1407000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3770000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
225829000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
113188000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
324782000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1287453000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
321012000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3770000 USD
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
27037000 USD
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
9904000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56602000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1685970000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
111781000 USD
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1407000 USD
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
24903000 USD
CY2021 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
50018000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105070000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1879113000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
231063000 USD
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5234000 USD
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
24367000 USD
CY2021 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
39142000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
120448000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2210615000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
111781000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
321012000 USD
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13630000 USD
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9141000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8348000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
119820000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
105070000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
56602000 USD
CY2021 exel Noncash Lease Expense
NoncashLeaseExpense
5332000 USD
CY2021 exel Noncash Lease Expense
NoncashLeaseExpense
4830000 USD
CY2020 exel Noncash Lease Expense
NoncashLeaseExpense
2819000 USD
CY2021 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-46529000 USD
CY2021 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-15265000 USD
CY2020 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-71002000 USD
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-23443000 USD
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3035000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-88000 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
122324000 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
42470000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-43716000 USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13209000 USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
21897000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5731000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
39875000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
25831000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5723000 USD
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
11008000 USD
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1051000 USD
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9301000 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
70297000 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
600000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4437000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
55090000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
50509000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
39687000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
400804000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
208982000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
526956000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64225000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30345000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12834000 USD
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1357168000 USD
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1070269000 USD
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1182682000 USD
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
1378509000 USD
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
969399000 USD
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
608269000 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42884000 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-131215000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-587247000 USD
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
24307000 USD
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
24886000 USD
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
22499000 USD
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
39108000 USD
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
50018000 USD
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
9904000 USD
CY2021 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2021 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2020 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-42000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14801000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25132000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12553000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
343119000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52635000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47738000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
320772000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268137000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
315875000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
663891000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
320772000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268137000 USD
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12960000 USD
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4115000 USD
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
7873000 USD
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4893000 USD
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4017000 USD
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
29562000 USD
CY2021 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
4000000 USD
CY2021 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
CY2020 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2739000 USD
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
842000 USD
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
26000 USD
CY2021 exel Investments Purchases Incurred But Not Yet Paid
InvestmentsPurchasesIncurredButNotYetPaid
0 USD
CY2021 exel Investments Purchases Incurred But Not Yet Paid
InvestmentsPurchasesIncurredButNotYetPaid
1615000 USD
CY2020 exel Investments Purchases Incurred But Not Yet Paid
InvestmentsPurchasesIncurredButNotYetPaid
0 USD
CY2021 exel Accounts Receivable For Unsettled Investment Sales
AccountsReceivableForUnsettledInvestmentSales
0 USD
CY2021 exel Accounts Receivable For Unsettled Investment Sales
AccountsReceivableForUnsettledInvestmentSales
6180000 USD
CY2020 exel Accounts Receivable For Unsettled Investment Sales
AccountsReceivableForUnsettledInvestmentSales
0 USD
CY2021 exel Number Of Countries With Drug Approval Excluding The Us
NumberOfCountriesWithDrugApprovalExcludingTheUS
61 country
CY2021 us-gaap Fiscal Period
FiscalPeriod
<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31st. Fiscal year 2021, which was a 52-week fiscal year, ended on December 31, 2021, fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal years ended January 1, 2021 and January 3, 2020 are indicated as being as of and for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reclassifications to our prior years’ Consolidated Financial Statements to conform to the current year’s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders’ equity.</span></div>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021 us-gaap Use Of Estimates
UseOfEstimates
The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021 exel Sales Revenue Percent Discount For Prompt Payment
SalesRevenuePercentDiscountForPromptPayment
0.02
CY2021 exel Sales Revenue Discount Expectedtobe Earned Percent
SalesRevenueDiscountExpectedtobeEarnedPercent
1
CY2021 exel Medicare Part D Funding Mandate
MedicarePartDFundingMandate
0.70
CY2021 exel Collaboration Agreement Percent Of Royalty On Net Sale
CollaborationAgreementPercentOfRoyaltyOnNetSale
0.03
CY2021 us-gaap Advertising Expense
AdvertisingExpense
31800000 USD
CY2021 us-gaap Advertising Expense
AdvertisingExpense
25100000 USD
CY2020 us-gaap Advertising Expense
AdvertisingExpense
17900000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1434970000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
987538000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
967775000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1434970000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
987538000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
967775000 USD
CY2020Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
26233000 USD
CY2021 exel Valuation Allowances And Reserves Additions For Sales In Current Period
ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
220748000 USD
CY2021 exel Valuation Allowances And Reserves Additions For Sales In Prior Period
ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
293000 USD
CY2021 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
216738000 USD
CY2021Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
30536000 USD
CY2021 exel Valuation Allowances And Reserves Additions For Sales In Current Period
ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
374208000 USD
CY2021 exel Valuation Allowances And Reserves Additions For Sales In Prior Period
ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
1449000 USD
CY2021 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
357868000 USD
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
48325000 USD
CY2021Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
1665000 USD
CY2021Q1 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
0 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7814000 USD
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1790000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8739000 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3755000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
16553000 USD
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5545000 USD
CY2021 exel Contract With Customer Liability Including New Contract Revenue Recognized
ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
8500000 USD
CY2021 exel Contract With Customer Liability Including New Contract Revenue Recognized
ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
9200000 USD
CY2020 exel Contract With Customer Liability Including New Contract Revenue Recognized
ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
6500000 USD
CY2021 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
148700000 USD
CY2021 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
169700000 USD
CY2020 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
161200000 USD
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
87500000 USD
CY2021Q4 exel Milestone Payments Earned To Date
MilestonePaymentsEarnedToDate
462500000 USD
CY2021 exel Collaboration Agreement Percent Of Royalty On Net Sale
CollaborationAgreementPercentOfRoyaltyOnNetSale
0.03
CY2021 exel Collaboration Agreement Percent Of Royalty On Net Sale
CollaborationAgreementPercentOfRoyaltyOnNetSale
0.03
CY2021 exel Collaboration Agreement Percent Of Royalty On Net Sale
CollaborationAgreementPercentOfRoyaltyOnNetSale
0.03
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
647169000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
319217000 USD
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16722000 USD
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1555000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
663891000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
320772000 USD
CY2021Q4 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
15200000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1534464000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
934000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1730000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1533668000 USD
CY2021Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1855704000 USD
CY2021Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
934000 USD
CY2021Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1730000 USD
CY2021Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
1854908000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1349982000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5931000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1355901000 USD
CY2021Q1 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1532923000 USD
CY2021Q1 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5931000 USD
CY2021Q1 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000 USD
CY2021Q1 us-gaap Interest Receivable
InterestReceivable
4500000 USD
CY2021Q1 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
1538842000 USD
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
2900000 USD
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
454780000 USD
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1730000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
56299000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
12000 USD
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
133 investment
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
14 investment
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1168256000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1034150000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
365412000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
321751000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1533668000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1355901000 USD
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
8867000 USD
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
7773000 USD
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
27717000 USD
CY2021Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
20610000 USD
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
12927000 USD
CY2021Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7291000 USD
CY2021Q4 us-gaap Inventory Gross
InventoryGross
49511000 USD
CY2021Q1 us-gaap Inventory Gross
InventoryGross
35674000 USD
CY2021Q4 us-gaap Inventory Gross
InventoryGross
49511000 USD
CY2021Q1 us-gaap Inventory Gross
InventoryGross
35674000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
144862000 USD
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
102068000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40831000 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34684000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
104031000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67384000 USD
CY2021 us-gaap Depreciation
Depreciation
13600000 USD
CY2021 us-gaap Depreciation
Depreciation
9100000 USD
CY2020 us-gaap Depreciation
Depreciation
8300000 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
119820000 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
105070000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56602000 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
119820000 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
105070000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56602000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
11004584 shares
CY2021 exel Share Based Compensation Arrangement By Share Based Payment Award Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
1 shares
CY2021 exel Share Based Compensation Arrangement By Share Based Payment Award Reduction In Share Reserve Due To Other Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
1.5 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
21000000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16129000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.72
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2573000 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
21.33
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4486000 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.23
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
545000 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
21.15
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13671000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.79
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y3M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
48860000000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9962000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.23
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y4M24D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
48171000000 USD
CY2021Q4 exel Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Maximum Potential To Vest
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
0.25
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
9500000 USD
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
6700000 USD
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
4600000 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
6095000 USD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
16562000 USD
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
11338000 USD
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
5224000 USD
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3791000 USD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3791000 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
6095000 USD
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
46416000 USD
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
14886000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
71580000 USD
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
113000 USD
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
379000 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-578000 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
46529000 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15265000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
71002000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63091000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19056000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77097000 USD
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
61772000 USD
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
27476000 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
83603000 USD
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1336000 USD
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2232000 USD
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1148000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2883000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5525000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3208000 USD
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6263000 USD
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
11356000 USD
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
8299000 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-11831000 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-20399000 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-9177000 USD
CY2021 exel Effective Income Tax Rate Reconciliation Nondeductible Expense Deferred Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
11182000 USD
CY2021 exel Effective Income Tax Rate Reconciliation Nondeductible Expense Deferred Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
18067000 USD
CY2020 exel Effective Income Tax Rate Reconciliation Nondeductible Expense Deferred Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
4228000 USD
CY2021 exel Effective Income Tax Rate Reconciliation Branded Prescription Drug Fee
EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
2897000 USD
CY2021 exel Effective Income Tax Rate Reconciliation Branded Prescription Drug Fee
EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
2537000 USD
CY2020 exel Effective Income Tax Rate Reconciliation Branded Prescription Drug Fee
EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
1099000 USD
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1115000 USD
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-562000 USD
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1287000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63091000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19056000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77097000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17993000 USD
CY2021Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37454000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
101460000 USD
CY2021Q1 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
126625000 USD
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
7764000 USD
CY2021Q1 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
18414000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
23162000 USD
CY2021Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
19818000 USD
CY2021Q4 exel Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
12385000 USD
CY2021Q1 exel Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
11908000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
19531000 USD
CY2021Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
12207000 USD
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8040000 USD
CY2021Q1 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
7637000 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1303000 USD
CY2021Q1 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
191638000 USD
CY2021Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
234063000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70068000 USD
CY2021Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67185000 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
121570000 USD
CY2021Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
166878000 USD
CY2021Q4 exel Deferred Tax Liabilities Lease Right Of Use Assets
DeferredTaxLiabilitiesLeaseRightOfUseAssets
9907000 USD
CY2021Q1 exel Deferred Tax Liabilities Lease Right Of Use Assets
DeferredTaxLiabilitiesLeaseRightOfUseAssets
9510000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0 USD
CY2021Q1 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
657000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
9907000 USD
CY2021Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
10167000 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
111663000 USD
CY2021Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
156711000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70100000 USD
CY2021Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67200000 USD
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2900000 USD
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5500000 USD
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
80941000 USD
CY2020Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
79078000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
76060000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
728000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
591000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
589000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2215000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3305000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2429000 USD
CY2021 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
301000 USD
CY2021 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
2033000 USD
CY2020 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
83583000 USD
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
80941000 USD
CY2020Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
79078000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
83600000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
52600000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
111781000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
321012000 USD
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
314884000 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
308271000 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
302584000 shares
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7475000 shares
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
9730000 shares
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5137000 USD
CY2020 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
12425000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
322359000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
318001000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
315009000 shares
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.73
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45122000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43010000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3025000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51272000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49086000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
56409000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
52111000 USD
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
5332000 USD
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
4825000 USD
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
2844000 USD
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
2685000 USD
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
2830000 USD
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
1024000 USD
CY2021 us-gaap Lease Cost
LeaseCost
8017000 USD
CY2021 us-gaap Lease Cost
LeaseCost
7655000 USD
CY2020 us-gaap Lease Cost
LeaseCost
3868000 USD
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
5000000 USD
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
4600000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
2900000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5638000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5995000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6283000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6478000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
6675000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
35170000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
66239000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9404000 USD
CY2021Q4 exel Lessee Operating Lease Liability Tenant Improvement Reimbursements
LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
426000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
56409000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.031
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M18D
CY2021Q4 us-gaap Tenant Improvements
TenantImprovements
36800000 USD
CY2021Q4 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
15200000 USD
CY2021 dei Auditor Firm
AuditorFirmId
42

Files In Submission

Name View Source Status
0000939767-22-000026-index-headers.html Edgar Link pending
0000939767-22-000026-index.html Edgar Link pending
0000939767-22-000026.txt Edgar Link pending
0000939767-22-000026-xbrl.zip Edgar Link pending
exel-20211231.htm Edgar Link pending
exel-20211231.xsd Edgar Link pending
exel-20211231_cal.xml Edgar Link unprocessable
exel-20211231_def.xml Edgar Link unprocessable
exel-20211231_g1.jpg Edgar Link pending
exel-20211231_g2.jpg Edgar Link pending
exel-20211231_htm.xml Edgar Link completed
exel-20211231_lab.xml Edgar Link unprocessable
exel-20211231_pre.xml Edgar Link unprocessable
exel20211231exhibit101.htm Edgar Link pending
exel20211231exhibit1018.htm Edgar Link pending
exel20211231exhibit1042.htm Edgar Link pending
exel20211231exhibit211.htm Edgar Link pending
exel20211231exhibit231.htm Edgar Link pending
exel20211231exhibit311.htm Edgar Link pending
exel20211231exhibit312.htm Edgar Link pending
exel20211231exhibit321.htm Edgar Link pending
exel20211231exhibit42.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_0a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending